EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

MULTIPLE MYELOMA: ETIOPATHOGENESIS, STAGING, DIAGNOSIS, TREATMENT AND RESPONSE ASSESSMENT

Helan Kurian*, Suja Abraham, Arpith Antony, Jeeva A. Jiju, Timy Thomas

ABSTRACT

Multiple myeloma (MM), also known as Kahler’s disease is an incurable haematological malignancy (plasma cell dyscrasia) of clonal B – cells of the plasma cells (a type of white blood cells in the bone marrow). Approximately 6.5% per lakh population are affected with multiple myeloma and is the second most common haematological malignancy. According to Indian Council of Medical Research (ICMR), in 2017 the global burden of MM has increased uniformly in the last 30 years and the global prevalence of MM accounts to 10,000 new cases every year in 1.4% per lakh population. The exact cause of MM is not established. Studies showed that, various factors contribute to the etiology of MM, such as genetic causes, environmental or occupational causes and Monoclonal Gammopathy of Undefined Significance (MGUS) or Smoldering MM (SMM). The first and foremost treatment goals of MM is to achieve a deep and long lasting clinical response, control of malignant cell growth and its spreading, to reduce complications of MM and to improve the quality of life in these patients. The selection of treatment regimen is completely patient specific and depends upon the baseline characteristics of the patient such as cytogenetic, disease stage, age, comorbidities and performance status of the patient. Multiple myeloma response criterias are used for determining the disease status for multiple myeloma and solitary plasmacytomas. To report the Stringent Complete Response (sCR) or Complete Response (CR), the urine studies are performed and should fulfil the International Myeloma Working Group (IMWG) criteria.

Keywords: multiple myeloma, response assessment, smoldering multiple myeloma, duries- salmon staging.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: NOVEMBER ISSUE PUBLISHED

    NOVEMBER 2024 issue has been successfully launched on NOVEMBER 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along witcertificate to promote resear activity of scholar.

Best Article of current issue :

Dr. Kartik Neog
Download Article : Click here